- [PDF]
UPUTSTVO ZA LEK
WEBLek Kisqali sadrži aktivnu supstancu ribociklib, koja pripada grupi lekova koji se nazivaju inhibitori ciklin-zavisne kinaze (CZK). Za šta se koristi lek Kisqali.
Ribociclib - Wikipedia
WEBRibociclib is a medication used to treat certain kinds of hormone receptor-positive, HER2-negative breast cancer. It is a kinase inhibitor that was developed by Novartis and Astex Pharmaceuticals and approved by FDA and EMA.
Ribociclib: Uses, Dosage, Side Effects, Warnings - Drugs.com
WEBJul 19, 2024 · Ribociclib is a targeted treatment used to treat breast cancer that is hormone receptor-positive, HER2-negative breast and has spread (metastasized) or cannot be removed by surgery. Ribociclib is given in combination with other cancer medicines such as letrozole (Femara) or fulvestrant (Faslodex).
Kisqali - European Medicines Agency (EMA)
WEBAug 31, 2017 · Kisqali is a combination of ribociclib and hormonal treatment for HR-positive, HER2-negative breast cancer. It is used to treat locally advanced or metastatic breast cancer in women before or after menopause.
Ribociclib as First-Line Therapy for HR-Positive, Advanced …
WEBNov 3, 2016 · Ribociclib (LEE011) is an orally bioavailable, selective, small-molecule inhibitor of CDK4/6 that blocks the phosphorylation of retinoblastoma protein, thereby preventing cell-cycle progression...
Kisqali (ribociclib) dosing, indications, interactions, adverse effects ...
WEBKisqali is a CDK inhibitor for hormone receptor-positive, HER2-negative breast cancer. Learn how to adjust the dose, monitor for toxicities, and avoid strong CYP3A inhibitors.
Kisqali: What to Expect, Side Effects, and More - Breastcancer.org
WEBKisqali (ribociclib) is a CDK4/6 inhibitor that slows cancer growth in hormone receptor-positive, HER2-negative breast cancer. Learn how it works, what to expect, and possible side effects.
WEBKisqali is a film-coated tablet for the treatment of hormone receptor-positive, HER2-negative breast cancer in combination with endocrine therapy. The product information provides details on indications, posology, dose modifications, adverse reactions and contraindications.
Ribociclib (Kisqali) - Breast Cancer Now
WEBRibociclib (Kisqali) is a targeted therapy drug that blocks the growth and spread of oestrogen receptor positive and HER2-negative breast cancer. It is taken with hormone therapy and can cause side effects such as low blood cells, infections and diarrhoea.
Kisqali 200 mg film-coated tablets - Summary of Product
WEBRibociclib is a strong CYP3A4 inhibitor at the 600 mg dose and a moderate CYP3A4 inhibitor at the 400 mg dose. Thus, ribociclib may interact with medicinal products which are metabolised via CYP3A4, which may lead to increased serum concentrations of CYP3A4 substrates (see section 4.5).